In a phase 2 study, Ojemda (tovorafenib) led to responses in 43% of adults with melanoma or other solid tumors that carried rare RAF gene changes. Ojemda (tovorafenib) shrank tumors in 10 of 23 adults ...
A recent clinical trial reveals how a daily statin pill may prevent heart attacks and strokes in people with HIV. In this substudy of the phase 3 Randomized Trial to Prevent Vascular Events in HIV ...
COURAGE Substudy: Anatomy Trumps Ischemia for Predicting Outcomes Among patients with stable ischemic heart disease, baseline assessment of anatomic burden predicts future events, but evaluation of ...
A recent ISCHEMIA trial substudy is under scrutiny from surgeons for a data discrepancy, rekindling concerns about reliance on the landmark trial data in the latest coronary revascularization ...
LOS ANGELES, CA—Among medically managed patients with acute coronary syndromes (ACS) but no ST-segment elevation, prasugrel is associated with lower platelet reactivity than clopidogrel, irrespective ...
DURHAM, N.C.--(BUSINESS WIRE)--Istari Oncology, Inc., a clinical-stage biotechnology company focused on development of the novel immune activator lerapolturev for the treatment of solid tumors, today ...
IRVINE, Calif., Sept. 2, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ)-- Johnson & Johnson MedTech, a global leader in cardiac arrhythmia treatment, today announced acute safety and effectiveness ...
The ITALIC-RCC study: A randomized study of clinical and humoral impact of primary tumor ablation in metastatic renal cell carcinoma treated with immunotherapy. This is an ASCO Meeting Abstract from ...
(RTTNews) - Johnson & Johnson (JNJ) MedTech, Tuesday announced results from the VARIPURE substudy of SECURE, evaluating the VARIPULSE Platform in pulsed field ablation procedures for atrial ...
Hosted on MSN
Daiichi Sankyo’s ADC push in gastroesophageal cancer: What substudy 06D means for investors
Daiichi Sankyo Company (DSKYF) announced an update on their ongoing clinical study. Study Overview: Substudy 06D, formally titled “A Phase 1/2 Open-Label, Umbrella Platform Design Study to Evaluate ...
Adding PCI to optimal medical therapy didn't improve clinical end points among the patients with stable CAD randomized in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results